Udvalget for Humanmedicinske Lægemidler (CHMP) noterede sig, at kombinationen af de to aktive stoffer i Azarga gør behandlingen mere enkel og gør det lettere for patienterne at overholde behandlingen.
The Committee for Medicinal Products for Human Use (CHMP) noted that combining the two active substances in Azarga simplifies therapy and helps patients to stick to their treatment.